Company Overview and News

 
Reliance Capital Limited - Updates

2018-10-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RELCAPITAL 500111

 
MF Wrap: Why mutual funds pared stake in NBFCs, HFCs in September?

2018-10-13 moneycontrol
Mutual funds pared stake in most non-banking and housing finance companies or NBFCs in September as defaults in repayment by group companies of Infrastructure Leasing & Financial Services (IL&FS) and subsequent ratings downgrades led to fears of a contagion in the sector.
511218 535789 IBULHSGFIN DHFL RELCAPITAL 511072 SRRQY IDKQY SRTRANSFIN 500111

 
Big win for Anil Ambani: Reliance Nippon gets Employee State Insurance Corp mandate to manage fund

2018-10-11 financialexpress
In a major fillip to Anil Ambani-run Reliance Nippon Life Asset management, the firm has received the mandate from Employees’ State Insurance Corporation (ESIC) to manage its funds. Notably, the total investment of ESIC stood at Rs 59,382 crore as on March 31, 2017.
RELCAPITAL 500111

 
Reliance Nippon Life Asset Management gets Employees#39; State Insurance Corp mandate to manage its funds

2018-10-11 moneycontrol
Reliance Nippon Life Asset Management (RNAM) on Thursday said it has received mandate from Employees' State Insurance Corporation to manage its funds.
RELCAPITAL 500111

 
Reliance Capital Limited - Updates

2018-10-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RELCAPITAL 500111

 
Reliance Capital Limited - Credit Rating

2018-10-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RELCAPITAL 500111

 
Won Jammu and Kashmir mediclaim policy contract after transparent process: Reliance General

2018-10-07 financialexpress
Reliance General Insurance said it has won the contract to provide health insurance cover to Jammu and Kashmir government staff after a rigorous and transparent competitive tender process. The company’s statement came after Congress president Rahul Gandhi alleged that the general insurance company, a wholly-owned subsidiary of Anil Ambani’s Reliance Capital, got the health insurance mandate from the J&K government due to his proximity to Prime Minister Narendra Modi.
RELCAPITAL 500111

 
Reliance Capital Limited - Issue of Securities

2018-10-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RELCAPITAL 500111

 
Anil Ambani’s latest foray: Reliance Health Insurance gets final nod from IRDAI

2018-10-05 financialexpress
Reliance Health Insurance, a wholly owned subsidiary of Anil Ambani-led Reliance Capital, has received final approval from the insurance regulator IRDAI to begin operations. The firm will start its operations by December quarter of 2018. “Reliance Health Insurance, a wholly owned subsidiary of Reliance Capital,announced that it has received R3 approval from IRDAI for its new health insurance business,” company said in an exchange filing.
RELCAPITAL 500111

 
Reliance Health Insurance gets final nod from Irdai to start ops

2018-10-05 moneycontrol
Anil Ambani-led Reliance Health Insurance, a wholly owned subsidiary of Reliance Capital, has received final approval from the insurance regulator to start operations. The company plans to commence operations by the December quarter of 2018.
RELCAPITAL 500111

 
Over 200 stocks hit new 52-week low on NSE as market sentiment remains weak, Uttam Value Steel tanks 50%

2018-10-05 moneycontrol
The Indian benchmark indices have extended the morning loses as the Nifty50 shed 121 points and is trading at 10,477 while the Sensex is down 294 points at 34,875.
IOC BAJAJ-AUTO RELCAPITAL GODREJIND 533273 530965 532977 ABAN 500182 533106 532178 OBZIY OBEROIRLTY OIL ENGINERSIN GAILY HEROMOTOCO GAILF HRTQY 523204 500164 500111

 
Reliance Capital Limited - Press Release

2018-10-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RELCAPITAL 500111

 

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...